Patel Amisha K, Kafi Aarya, Bonet Antonio, Shapiro Shelly M, Oh Scott S, Zeidler Michelle R, Betancourt Jaime
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Pulmonary and Critical Care Section, Department of Medicine, West Los Angeles Veterans Affairs Healthcare Center and the David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J Intensive Care Med. 2016 Oct;31(9):618-21. doi: 10.1177/0885066616646539. Epub 2016 May 2.
Right heart thrombus in transit (RHTT) is a rare, severe form of venous thromboembolism that carries a high mortality rate. The optimal treatment for RHTT has not been well established. Thrombolysis is a therapeutic modality for RHTT but carries the risk of bleeding complications including intracranial hemorrhage. Low-dose thrombolysis has been shown to be effective in treating submassive pulmonary emboli without an increased risk in bleeding complications, but it has not been studied in patients with RHTT. Here, we discuss the case of a 74-year-old male with lung cancer and recent craniotomy with metastasectomy 30 days prior to admission presenting with RHTT and bilateral pulmonary emboli (PE). He was treated successfully with low-dose thrombolysis, despite his relative contraindication to thrombolytics. To our knowledge, this is the first reported case of low-dose alteplase (tissue plasminogen activator [tPA]) used to treat an in-transit PE in the setting of recent craniotomy with metastasectomy.
移动性右心血栓(RHTT)是一种罕见且严重的静脉血栓栓塞形式,死亡率很高。RHTT的最佳治疗方法尚未完全确立。溶栓是RHTT的一种治疗方式,但存在包括颅内出血在内的出血并发症风险。低剂量溶栓已被证明可有效治疗亚大面积肺栓塞且不增加出血并发症风险,但尚未在RHTT患者中进行研究。在此,我们讨论一例74岁男性患者,患有肺癌,入院前30天接受了开颅转移瘤切除术,现出现RHTT和双侧肺栓塞(PE)。尽管他相对禁忌使用溶栓药物,但仍通过低剂量溶栓成功治疗。据我们所知,这是首例报道使用低剂量阿替普酶(组织纤溶酶原激活剂[tPA])治疗近期开颅转移瘤切除术后发生的移动性肺栓塞的病例。